Table 3.
Cox regression analysis for prediction of all-cause mortality.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age (years) | 1.05 (0.99–1.12) | 0.097 | 1.02 (0.93–1.12) | 0.667 |
| Male | 1.35 (0.27–6.71) | 0.712 | — | — |
| Ethnicity | 0.57 (0.15–2.11) | 0.405 | — | — |
| CTD-related PAH | 2.82 (0.7–11.3) | 0.144 | — | — |
| Severe RVEDV/LVEDV | 24.1 (2.97–196) | 0.003 | 24.9 (1.18–527) | 0.039 |
| RVEDVi | 1.02 (1.01–1.03) | 0.000 | 1.03 (1.01–1.06) | 0.008 |
| RVEF | 0.91 (0.84–0.98) | 0.011 | 1.26 (1.07–1.49) | 0.005 |
| RVSV | 1.00 (0.97–1.04) | 0.601 | — | — |
| LVEDVi | 1.01 (0.98–1.06) | 0.355 | — | — |
| LVEF | 0.86 (0.77–0.95) | 0.004 | 0.83 (0.71–0.96) | 0.016 |
| LVSV | 0.98 (0.94–1.02) | 0.316 | — | — |
| NT-proBNP | 1 (1.00–1.01) | 0.000 | 1 (1.00–1.002) | 0.073 |
| 6MWT | 0.99 (0.99–1.01) | 0.105 | — | — |
| NYHA functional class | ||||
| NYHA I | 1 | 0.393 | — | — |
| NYHA II | 0.42 (0.08–2.1) | 0.290 | — | — |
| NYHA III | 1.31 (0.21–8.0) | 0.768 | — | — |
CTD, connective tissue disease; PAH, pulmonary artery hypertension; RVEDVi, right ventricular end-diastolic volume index; RVEF, right ventricular ejection fraction; RVSV, right ventricular stroke volume; LVEDVi, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVSV, left ventricular stroke volume; 6MWT, six-minute walk test; -, insignificant.